Steven Cohen’s Nektar Therapeutics NKTR Stock Holding History

Steven Cohen’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,000	Closed	-$381K	–	4252
2025 Q4	$381K	Sell	9,000 -23,500	-72%	-$1.32M	﹤0.01%	3373
2025 Q3	$1.85M	Buy	+32,500	New	+$1.08M	﹤0.01%	1471
2019 Q4	–	Sell	-5,533	Closed	-$1.51M	–	1151
2019 Q3	$1.51M	Buy	+5,533	New	+$2.03M	0.01%	630

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's NKTR Position: Q2 2026 in Review

Steven Cohen sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 13,364 shares — an estimated $962K sold.

Steven Cohen first reported a position in NKTR in Q3 2015 and held it in 13 quarters. The position peaked at $18.3M in Q4 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Steven Cohen reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 13,364 Nektar Therapeutics shares in Q2 2026, an estimated $962K.
Steven Cohen first reported a position in Nektar Therapeutics in Q3 2015 and held it in 13 quarters.
Steven Cohen's Nektar Therapeutics position peaked at $18.3M in Q4 2025.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.